Literature DB >> 28177792

Utilization of carbon sources by clinical isolates of Aeromonas.

Karoline C Prediger1, Monica Surek1, Cibelle B Dallagassa1, Flávia E A Assis1, Mario S Piantavini2, Emanuel M Souza3, Fábio O Pedrosa3, Sônia M S S Farah4, Dayane Alberton1, Cyntia M T Fadel-Picheth1.   

Abstract

Bacteria in the genus Aeromonas are primarily aquatic organisms; however, some species can cause diseases in humans, ranging from wound infections to septicemia, of which diarrhea is the most common condition. The ability to use a variety of carbon substrates is advantageous for pathogenic bacteria. Therefore, we used Biolog GN2 microplates to analyze the ability of 103 clinical, predominantly diarrheal, isolates of Aeromonas to use various carbon sources, and we verified whether, among the substrates metabolized by these strains, there were some endogenous to the human intestine. The results indicate that Aeromonas present great diversity in the utilization of carbon sources, and that they preferentially use carbohydrates and amino acids as carbon sources. Among the carbon sources metabolized by Aeromonas in vitro, some were found to be components of intestinal mucin, including aspartic acid, glutamic acid, l-serine, galactose, N-acetyl-glucosamine, and glucose, which were used by all strains tested. Additionally, mannose, d-serine, proline, threonine, and N-acetyl-galactosamine were used by several strains. The potential to metabolize substrates endogenous to the intestine may contribute to Aeromonas' capacity to grow in and colonize the intestine. We speculate that this may help explain the ability of Aeromonas to cause diarrhea.

Entities:  

Keywords:  Aeromonas; Biolog; carbon source; mucin; mucine; source de carbone

Mesh:

Substances:

Year:  2016        PMID: 28177792     DOI: 10.1139/cjm-2016-0526

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  1 in total

1.  Virulence characteristics and antimicrobial resistance of Aeromonas veronii biovar sobria 312M, a clinical isolate.

Authors:  Karoline de C Prediger; Cibelle B Dallagassa; Bárbara Moriel; Bruno Stefanello Vizzotto; Waldemar Volanski; Emanuel M Souza; Fábio O Pedrosa; Vinícius Weiss; Dayane Alberton; Dieval Guizelini; Cyntia M T Fadel-Picheth
Journal:  Braz J Microbiol       Date:  2019-11-09       Impact factor: 2.476

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.